Overview
Thromboangiitis obliterans (TAO), also known as Buerger's disease, is a non-atherosclerotic, segmental inflammatory disease primarily affecting small and medium-sized blood vessels, predominantly in the lower extremities. Its etiology and pathophysiology remain poorly understood, complicating diagnosis and management. 1Diagnosis
Clinical Presentation: Characterized by episodic limb ischemia, typically affecting lower extremities more frequently than upper extremities. 5
Exclusion Criteria: Negative for Antineutrophil Cytoplasmic Antibodies (ANCA) in both active and inactive disease states. 3
Diagnostic Challenges: Lack of specific biomarkers and disease activity markers complicates clinical assessment. 1
Platelet Function Tests: Consider evaluating platelet activation and function using advanced hematology analyzers for potential insights, though not standard. 2
Glucocorticoid Receptor Analysis: Lower glucocorticoid receptor content in circulating lymphocytes may correlate with disease severity; further validation needed. 4Management
Smoking Cessation: Essential first step in management, as smoking is a primary risk factor. 1
Medical Therapy: Limited specific drug recommendations; focus on symptomatic relief and prevention of complications. 1
Operative Procedures: Consider local operative procedures as alternatives to lumbar sympathectomy in early cases to manage lower limb involvement effectively. 5
Glucocorticoids: Potential role based on receptor content analysis, though specific dosing not detailed. 4
Supportive Care: Includes pain management, physiotherapy, and vascular support measures. 1Special Populations
Pregnancy: No specific guidelines provided in the abstracts. 1
Pediatrics: Limited data; management likely follows adult guidelines with caution. 1
Elderly: Management considerations similar to adults, with emphasis on comorbidities and functional status. 1
Comorbidities: Focus on managing coexisting conditions that may exacerbate TAO symptoms or complications. 1Key Recommendations
Implement Smoking Cessation Programs: Critical for all patients with TAO to halt disease progression. (Evidence: Expert opinion) 1
Consider Local Operative Procedures: For early-stage lower limb involvement as an alternative to lumbar sympathectomy. (Evidence: Moderate) 5
Monitor Glucocorticoid Receptor Levels: May provide prognostic insights, though further research is needed for clinical utility. (Evidence: Weak) 4
Exclude ANCA in Diagnostic Workup: To rule out other vasculitides mimicking TAO. (Evidence: Strong) 3References
1 Fazeli B, Poredos P, Patel M, Klein-Weigel P, Catalano M, Stephen E et al.. Milestones in thromboangiitis obliterans: a position paper of the VAS-European independent foundation in angiology/vascular medicine. International angiology : a journal of the International Union of Angiology 2021. link
2 Bennaoum MN, Lazreg H, Adda A, Hammadi M. A new proposition for the screening of platelet function defects using an hematology analyzer. Medical hypotheses 2017. link
3 Schellong SM, Rautmann A, Gross WL, Alexander K. No ANCA in thromboangiitis obliterans (Bürger's disease). Advances in experimental medicine and biology 1993. link
4 Krasznai A, Krajcsi P, Arányi P, Horváth I. Glucocorticoid receptors in thromboangiitis obliterans. International journal of clinical pharmacology, therapy, and toxicology 1987. link
5 Kamath MV. Thromboangiitis obliterans--its overwhelming incidence in lower limbs; a plausible explanation. Angiology 1985. link